Advanced in Childhood Iron Deficiency Anemia

Dr. Timothy H. Dorius

Hematology | Oncology | Hematology Oncology
Oncology Hematology West, PC
8303 Dodge St, Suite 250, 
Omaha, NE 
Accepting New Patients
Advanced in Childhood Iron Deficiency Anemia
Oncology Hematology West, PC
8303 Dodge St, Suite 250, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Dorius is a Hematologist and an Oncologist in Omaha, Nebraska. Dr. Dorius is rated as an Advanced provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Gastrostomy. Dr. Dorius is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in NE
Hospital Affiliations
The Nebraska Methodist Hospital
Chi Health Lakeside
Methodist Jennie Edmundson
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY WEST, PC
8303 Dodge St, Suite 250, Omaha, NE 68114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological, Procedure, Radiation
Study Drug: Durvalumab
Study Phase: Phase 1
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug
Study Drug: Crofelemer [Mytesi]
Study Phase: Phase 3
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

2 Total Publications

Weight Loss and Percutaneous Endoscopic Gastrostomy Tube Placement during Chemoradiotherapy for Locally Advanced Cancer of the Oropharynx Do Not Negatively Impact Outcomes.
Weight Loss and Percutaneous Endoscopic Gastrostomy Tube Placement during Chemoradiotherapy for Locally Advanced Cancer of the Oropharynx Do Not Negatively Impact Outcomes.
Journal: Frontiers in oncology
Published: June 12, 2017
Similar Doctors
Distinguished in Childhood Iron Deficiency Anemia
Dr. Sakeer Hussain
Hematology Oncology | Oncology | Hematology
Distinguished in Childhood Iron Deficiency Anemia
Dr. Sakeer Hussain
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

1 Edmundson Pl, Suite 100, 
Council Bluffs, IA 
 (10.7 miles away)
712-322-4136
Languages Spoken:
English, Burmese, Hindi, Malay, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Sakeer Hussain is a Hematologist Oncology specialist and an Oncologist in Council Bluffs, Iowa. Dr. Hussain is rated as a Distinguished provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Chronic Familial Neutropenia, Paget Disease of the Breast, Colorectal Cancer, and Lynch Syndrome. Dr. Hussain is currently accepting new patients.

Distinguished in Childhood Iron Deficiency Anemia
Dr. Abraham P. Mathews
Hematology Oncology | Hematology | Oncology
Distinguished in Childhood Iron Deficiency Anemia
Dr. Abraham P. Mathews
Hematology Oncology | Hematology | Oncology

Alegent Creighton Clinic

16909 Lakeside Hills Ct, 
Omaha, NE 
 (7.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Abraham Mathews is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Mathews is rated as a Distinguished provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Childhood Iron Deficiency Anemia, and Lung Cancer. Dr. Mathews is currently accepting new patients.

Distinguished in Childhood Iron Deficiency Anemia
Dr. Nagendra K. Natarajan
Hematology Oncology | Pediatrics | Hematology
Distinguished in Childhood Iron Deficiency Anemia
Dr. Nagendra K. Natarajan
Hematology Oncology | Pediatrics | Hematology

Oncology Hematology West, PC

7500 Mercy Rd, Suite 1300, 
Omaha, NE 
 (1.4 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nagendra Natarajan is a Hematologist Oncology specialist and a Pediatrics provider in Omaha, Nebraska. Dr. Natarajan is rated as a Distinguished provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Thrombocytopenia. Dr. Natarajan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dorius's expertise for a condition
ConditionClose
    View All 36 Advanced Conditions
    View All 123 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile